After completing this activity, learners should be able to: – Summarize real world clinical data associated with newer and emerging immunotherapeutic options in R/R MM, including CAR T-cell therapy and BsAbs, and their potential TRAEs – Describe how to promptly recognize, triage, diagnose, and manage the most common TRAEs and toxicities associated with R/R MM therapies – Evaluate current guidelines/protocols available to address AEs associated with the disease process as well as TRAEs in MM – Implement strategies for multidisciplinary care coordination for managing AEs
- Provider:HMP Education
- Activity Link: https://www.hmpeducation.com/program/24onccme1091
- Start Date: 2024-10-30 05:00:00
- End Date: 2024-10-30 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABS - 1.5 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: Janssen (Any division) - Amount: 0 - Is Kind Support: False Source: Legend Biotech - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Limited
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest